<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Clinical experiment of indigo naturalis in treating UC</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Drugs</th>
    <th align="left">Clinic types of experiments</th>
    <th align="left">Number of examinees</th>
    <th align="left">Usage time</th>
    <th align="left">Results</th>
    <th align="left">Adverse reactions</th>
    <th align="left">Refs.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Indigo naturalis</td>
    <td align="left">Retrospective observational study</td>
    <td align="left">n = 14</td>
    <td align="left">8 weeks</td>
    <td align="left">In 10 active UC patients 50% had clinical response and 40% achieved clinical remission. Rachmilewitz endoscopic index (REI), and UC endoscopy index of severity (UCEIS). the Mayo endoscopic subscore (MES) decreased from 2 (2–3) to 1 (1–2), the Rachmilewitz endoscopic index (REI) decreased from 7 (5.5–11) to 3 (1–7), and the UC endoscopy index (UCEIS) of severity decreased from 3 (3-4.5) to 1 (0.5–3.5)</td>
    <td align="left">One patient developed right colitis with intestinal wall thickening and edema</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR88">88</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Indigo naturalis oil suppository</td>
    <td align="left">Open-label, single-center, prospective pilot study</td>
    <td align="left">n = 10</td>
    <td align="left">4 weeks</td>
    <td align="left">30% of patients achieved clinical remission, 40% of patients had mucosal healing. Mucosal healing was observed in 80% of patients with MES in the Rectum (R-MES) score of 2, but not in patients with scores of 3</td>
    <td align="left">One patient developed perianal pain</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR89">89</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Indigo naturalis</td>
    <td align="left">A multicenter, double-blind trial</td>
    <td align="left">n = 86</td>
    <td align="left">8 weeks</td>
    <td align="left">The clinical response of UC was correlated with the oral dose of indigo naturalis. 13.6% of patients had clinical response to placebo; 69.6% to 0.5 g indigo naturalis; 75.0% to 1.0 g indigo naturalis and 81.0% to 2.0 g indigo naturalis. At week 8, 56.6% patients with 0.5 g, 60% with 1.0 g and 47.6% with 2.0 g indigo naturalis received clinical relief compared to 13.6% placebo</td>
    <td align="left">Mild liver dysfunction was observed in 10 patients taking indigo naturalis, but there were no significant adverse reactions. Unfortunately, the experiment was terminated because a patient took indigo naturalis by heself and developed pulmonary hypertension</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR90">90</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Indigo naturalis</td>
    <td align="left" rowspan="2">Retrospective observational study</td>
    <td align="left" rowspan="2">
     <p>n = 17 in UC</p>
     <p>and n = 8 in Crohn’s disease (CD)</p>
    </td>
    <td align="left">8 weeks</td>
    <td align="left">There are 94.1% and 88.2% in UC and 37.5% and 25.0% in CD receiving Clinical response and clinical remission, respectively</td>
    <td align="left" rowspan="2">During follow-up, 10 patients developed adverse reactions, and 3 patients experienced severe adverse reactions, including 2 cases of acute colitis requiring hospitalization and 1 case of acute colitis intussusception requiring surgical treatment</td>
    <td align="left" rowspan="2">[
     <xref ref-type="bibr" rid="CR91">91</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">
     <p>52 weeks</p>
     <p>And 104 weeks</p>
    </td>
    <td align="left">Through non-responders imputation analyses at weeks 52 and 104, the clinical remission rates were 76.4% and 70.4% in UC patients and 25.0% and 25.0% in CD patients</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
